# Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
Canonical URL: https://biopharmsignal.com/news/TARS/tarsus-to-report-first-quarter-2026-financial-results-on-wednesday-may-6-2026
Ticker: TARS
Company: Tarsus Pharmaceuticals
Source: Tarsus Pharmaceuticals
Published: 2026-04-29 20:30 EST
Original Source URL: https://ir.tarsusrx.com
## Summary

IRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, May 6, 2026 to report its first quarter 2026 financial results and provide a corporate update.

## Article Body
IRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, May 6, 2026 to report its first quarter 2026 financial results and provide a corporate update.
## Recent Company News
- 2026-05-14 12:30 EST — [Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans](https://biopharmsignal.com/news/TARS/tarsus-and-john-cena-partner-to-raise-awareness-of-demodex-blepharitis-a-common-eyelid-disease-affecting-approximately-25-million-americans) — Source: Tarsus Pharmaceuticals
- 2026-05-06 20:05 EST — [Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements](https://biopharmsignal.com/news/TARS/tarsus-reports-first-quarter-2026-financial-results-and-recent-business-achievements) — Source: Tarsus Pharmaceuticals
- 2026-04-29 20:30 EST — [Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026](https://biopharmsignal.com/news/TARS/tarsus-to-report-first-quarter-2026-financial-results-on-wednesday-may-6-2026) — Source: Tarsus Pharmaceuticals
- 2026-03-31 12:30 EST — [Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease](https://biopharmsignal.com/news/TARS/tarsus-doses-first-participant-in-calliope-a-phase-2-clinical-trial-of-tp-05-lotilaner-a-novel-investigational-oral-tablet-for-the-potential-prevention-of-lyme-disease) — Source: Tarsus Pharmaceuticals
- 2026-03-23 12:30 EST — [TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus](https://biopharmsignal.com/news/TARS/tp-03-lotilaner-ophthalmic-solution-0-25-now-approved-in-china-for-the-treatment-of-demodex-blepharitis-triggering-a-15m-milestone-payment-to-tarsus) — Source: Tarsus Pharmaceuticals
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)